Company: IMCR
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012123
Chunk: 71

Company: Immunocore Holdings plc
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 71
---
 Metric                 |     | Weight |     | Goals                                                                                                                                                                                                                |     | Achievement |     | Weighted    
 Achievement |
| Lead in TCR Innovation |     | 50%    |     | Goals focused on executing our clinical trials, building our pipeline for new products, completing regulatory submissions, high impact publications and other related matters                                        |     | 95.2%       |     | 47.6%       |
| Grow the Business      |     | 40%    |     | Goals pertaining to commercial and other matters, including related to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development |     | 103.5%      |     | 41.4%       |
| Be the Best Workplace  |     | 10%    |     | Goals related to recruiting, employee engagement, compliance, workforce planning, culture and other employee matters                                                                                                 |     | 108%        |     | 10.8%       |
|                        |     |        |     | Initial Calculated Achievement                                                                                                                                                                                       |     |             |     | 99.8%       |
|                        |     |        |     | Adjusted Achievement (See Below)                                                                                                                                                                                     |     |             |     | 100%        |

48

TABLE OF CONTENTS

The remuneration committee assesses corporate performance goal achievement each fiscal year. In January 2025, the remuneration committee assessed 2024 performance against the corporate scorecard and initially determined that the goals were achieved at 99.8%, as summarized in the table above. However, in light of solid achievement of specific corporate goals, including those noted in the table below, the remuneration committee approved a very slight lift in the overall achievement percentage to 100%, which the remuneration committee determined was appropriate to reward the hard work and accomplishments across our entire company.

| Metric                 |                                                                                       |     | Goal                                                                                                              |                                                                        |     | Achievement                                                                                                                                                              |
| Lead in TCR Innovation |                                                                                       |     | Various detailed goals around delivering on our pipeline                                                          |                                                                        |     | Goals Achieved:                                                                                                                                                          
 •Reported data on three Phase 1 trials to expand our pipeline beyond KIMMTRAK for mUM                                                                                    
 •Delivered commercial-scale manufacturing and initiated process validation for PRAME-A2                                                                                  
 •First patient randomized in Phase 3 PRISM-MEL and KIMMTRAK ATOM trials                                                                                                  
 •First patients dos